Synergy Pharmaceuticals Inc. Raises $200M Rule 144A Offering of 7.50% Convertible Senior Notes
Sichenzia Ross Friedman Ference LLP Represents Synergy Pharmaceuticals Inc. in $200M Rule 144A Offering of 7.50% Convertible Senior Notes
New York, NY – (Global Newswire, November 5, 2014) – New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced that it represented Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical developer of drugs to treat gastrointestinal disorders and diseases, in a Rule 144A offering of $200 million of 7.50% Convertible Senior notes. The notes are convertibles into shares of Synergy Pharmaceutical’s common stock at a conversion price of approximately $3.11 per share.
The SRFF team was led by Partner Jeffrey J. Fessler.
- Two Bright Sides of Estate Planning During COVID-19 - July 1, 2020
- Sichenzia Ross Ference LLP Represents Aegis Capital in $5.4 Million Public Offering of Avinger, Inc. Common Stock - June 26, 2020
- Sichenzia Ross Ference LLP Represents Hudson Capital Inc. in $3.7 Million Registered Direct Offering - June 24, 2020